Here’s what you need to know:
1. Dr. Cominelli is the chief of the division of gastroenterology and liver disease at Case Western Reserve University School of Medicine, director of the digestive health institute at Case Western Reserve University School of Medicine and chief scientific officer of the digestive health institute at University Hospitals Cleveland Medical Center, all of which are located in Cleveland.
2. XBiotech develops therapeutic antibodies for the treatment of inflammatory conditions, infectious diseases and tumors; the company’s antibody therapy, for example, can be used to neutralize inflammation.
3. Dr. Cominelli’s research team at Case Western Reserve University School of Medicine will conduct preclinical studies with XBiotech’s antibody therapy, in an effort to develop new inflammatory bowel disease treatments.
More articles on gastroenterology and endoscopy:
Allergan taps paratriathlete Amy Dixon as spokesperson for IBS
50% of patients treated with Kanuma experience reduced liver fibrosis: 3 study insights
Takeda Pharmaceutical, New York Academy of Sciences establish $200k research prize: 3 notes
